Table 2.
Central macular thickness (CMT) and total macular volume (TMV) before and at 1 month and 3 months after cataract surgery, and the incidence of postoperative macular edema (PME).
| Bevacizumab group | Control group | P-value | |
|---|---|---|---|
| CMT, preop, μm | 261.4 ± 24.3 | 267.5 ± 27.4 | 0.303 |
| CMT, 1 month postop, μm | 267.3 ± 31.8 | 293.6 ± 53.7 | 0.019 |
| CMT, 3 months postop, μm | 264.5 ± 21.9 | 291.4 ± 79.8 | 0.089 |
| TMV, Preop | 8.39 ± 0.54 | 8.40 ± 0.51 | 0.937 |
| TMV, 1 month postop | 8.40 ± 0.62 | 8.63 ± 0.70 | 0.147 |
| TMV, 3 months, postop | 8.49 ± 0.50 | 8.71 ± 0.71 | 0.140 |
| BCVA, Preop, logMAR | 0.54 ± 0.21 | 0.46 ± 0.16 | 0.137 |
| BCVA, 1 month postop | 0.07 ± 0.06 | 0.10 ± 0.09 | 0.226 |
| BCVA, 3 months postop | 0.06 ± 0.04 | 0.06 ± 0.06 | 0.622 |
| PME, 1 month postop, n, % | 2 (%5.5) | 5 (%14.7) | 0.244 |
| PME, 3 months postop, n, % | 3 (%8.33) | 8 (%22.8) | 0.076 |
CMT: Central macular thickness; TMV: Total macular Volume; BCVA: Best corrected visual acuity; PME: Postoperative macular edema.